Literature DB >> 11369959

Seroprevalence of hepatitis A virus markers in Eastern Saudi Arabia.

S E Fathalla1, A A Al-Jama, I H Al-Sheikh, S I Islam.   

Abstract

OBJECTIVE: To record and update the sero-epidemiological status of Hepatitis A virus in Eastern Saudi Arabia. To investigate the main viral etiology of clinical hepatitis in children and discuss the possibility of introducing a Hepatitis A virus vaccine in this Province.
METHODS: Examining serum specimens by Enzyme Linkage Immuno-Sorbet Assay technique for these parameters: Immunoglobulin M anti-hepatitis A virus, total immunoglobulin anti-hepatitis A virus, and in selected cases we checked for hepatitis B surface antigen and anti-hepatitis C virus. The study was carried out in the Virology Diagnostic Labs, of Dammam Regional Laboratories & Blood Bank, Dammam. A total of 12,357 serum samples were collected from 5876 healthy children, 5798 healthy adults, and 683 from clinically diagnosed hepatitis in children. The period of study was 12 years from February 1987 to January 1999.
RESULTS: Hepatitis A virus prevalence showed 3% for pre-school age, 80% in older children and 93% in adults, while total prevalence was 86%. Breaking down the prevalence among children showed 3% in the <6 years age group, 62% in the 6 - <8 years age group, 71% in the 8 - <10 years age group, 83% in the 10 - <12 years age group and 93% in the 12 - <18 years age group. While the grand total among children was 78%. The prevalence of hepatitis viruses causing clinical hepatitis in children showed: 65% for hepatis A virus, 21% for hepatitis B virus, 7% for hepatitis C virus, 2% for double infection of hepatitis B virus + hepatitis C virus and 5% for non A, non B, non C.
CONCLUSION: Hepatitis A virus infection starts dramatically high in school-age children, and then rises gradually with an increase in age. This reflects that our region is of pattern I class. There is no difference in the prevalence due to seasons of year, climate or sex. Hepatitis A virus is the leading cause of clinical hepatitis in children, followed by hepatitis B virus and hepatitis C virus. There is a possibility of starting to introduce hepatitis A virus vaccine among pre-school age children, as well as among hepatitis A virus negative adults that live in a higher socioeconomic environment within the country, which can be considered as islands of pattern II among pattern I areas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11369959

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  6 in total

1.  Seroepidemiology of hepatitis A virus in Kuwait.

Authors:  Jameela Alkhalidi; Bader Alenezi; Seham Al-Mufti; Entisar Hussain; Haifa Askar; Nyingi Kemmer; Guy W Neff
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

2.  Confirmed Foodborne Hepatitis A in Saudi Arabia, 2005-2015.

Authors:  Jaber Sharaheeli; Bader Alibrahim
Journal:  Cureus       Date:  2022-01-02

Review 3.  Sexually acquired hepatitis.

Authors:  M G Brook
Journal:  Sex Transm Infect       Date:  2002-08       Impact factor: 3.519

Review 4.  Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran.

Authors:  Ziba Farajzadegan; Shervin Ghaffari Hoseini; Roya Kelishadi; Fahimeh Jamshidi; Zari Nokhodian; Rasool Noori; Parisa Mirmoghtadaee; Silva Hovsepian; Seyyed-Nassereddin Mostafavi
Journal:  J Res Med Sci       Date:  2014-03       Impact factor: 1.852

Review 5.  Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook?

Authors:  Ayman A Abdo; Faisal M Sanai; Faleh Z Al-Faleh
Journal:  Saudi J Gastroenterol       Date:  2012 Nov-Dec       Impact factor: 2.485

Review 6.  A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region.

Authors:  Selim Badur; Serdar Öztürk; Alev Ozakay; Mansour Khalaf; Debasish Saha; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2021-07-02       Impact factor: 4.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.